Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. - Wikidata - awgldk - TriplyDB

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.

http://www.wikidata.org/entity/Q35172210

about

Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients Pediatric AML: From Biology to Clinical Management How I treat pediatric acute myeloid leukemia Childhood acute myeloid leukaemia Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide Molecular therapy for acute myeloid leukaemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia Cardiovascular disease in adult survivors of childhood cancer.The Biology and Targeting of FLT3 in Pediatric Leukemia.Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.Novel agents for the treatment of childhood acute leukemia.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Ontogeny and sorafenib metabolism.Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.Advances in paediatric cancer treatment Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group Nexavar/Stivarga and viagra interact to kill tumor cells.GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3.Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells Alternative formulations of sorafenib for use in children.Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Sorafenib Induced Hand Foot Skin Rash in FLT3 ITD Mutated Acute Myeloid Leukemia-A Case Report and Review of Literature.Pediatric acute myeloid leukemia.Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

P2860

Q26799609-8B294EDD-CDB5-41F7-914F-BD4458ADA01D Q26799773-CC09C0B1-780C-43EF-B10E-BBE6D82FE0AB Q26992280-98D04199-829A-4662-9ED8-A2CA9BF8586F Q27005960-CD007ECD-563F-4B60-898E-A691747FE02C Q27852520-BCF13750-3423-42CD-95C3-0B884119CB1F Q30244600-B73E2F6D-0986-478A-9ADA-B7863531A28E Q33401352-A541ECD5-00DB-48D9-A2F3-995F2F2160AE Q33403207-EAA9CD9A-EF55-4FA5-B336-8565A8FA22D1 Q33428775-2EFBFF7F-AFA2-44D4-9F2C-B8AFFA45B67C Q33891564-A60E8B21-DC1A-4720-9B28-599B73C6379D Q33925672-16ECDA85-2A70-4603-B737-5FFD01E0BECB Q33943277-3F1BFFB5-1875-45F9-BF2E-DCB8E183ED1C Q34042984-EC6C6162-56C5-48E4-BAB5-42EA42DAF4EB Q34229555-83F4323E-A065-45F0-9CE4-B8358DD87C57 Q35021664-AFE25DF8-FE58-4605-8414-B51C87AB5449 Q35192790-749E528E-A36B-42CF-BEF9-EF2C317CC6F3 Q35562745-5A9CAFEF-33F4-44C6-8A2B-2480F54D19FE Q35750567-8E9413A6-4BA0-4601-A553-5B4F6A24925E Q35812091-0A844151-5BAE-4B18-9D11-07C13BC17113 Q35891218-A4B37FD0-5BCF-4ED6-BF7F-5BD8D4356DCA Q36038920-F5F5EA9A-7E7F-4D79-9107-4EDE1B126099 Q36163029-EF91031F-AEF8-41FC-8BCD-59D1ABBACBCE Q36270115-6E28D31C-5EE2-4D71-8931-C32C0696F28A Q36375706-544F6B10-0C1B-4B0D-AC9B-C480348CE440 Q36463168-77E216EC-694F-4252-B086-F11E5911C0DE Q36508630-531A24C3-3F47-4A71-A713-28D88BBC1281 Q36511158-78F8647C-B99D-4272-A8EB-0FDDF7CC9CA4 Q36804215-987E39DC-3588-423A-96BF-EF30DC6327B2 Q36805474-453F14AA-ABFD-45C7-97B0-582F215D8F00 Q36808335-D55F5540-008B-4FC5-BCE8-86516460A543 Q36830763-D0E6BF97-F35F-4FD3-B712-384F24AAD84A Q37024596-298066DA-E8F9-410D-AD91-8768E98A54A2 Q37104378-ED8280BE-3E45-4F2B-84E2-ADA79293FF2E Q37213049-98D4AA98-13E3-468C-B456-F3838F59E1C4 Q37239947-14B4A88C-0F3C-4ECE-9035-7BFBDBAE3019 Q37615574-6A090AA3-87EA-4E9B-ADFC-CF44313AF464 Q37643136-D30B3C47-05BD-4652-995C-6B47FBCF44CF Q37663028-536F0B86-9D87-434E-8476-D18F35C3128D Q37988570-02FB63B3-D816-4B63-9FE2-0036C40B9245 Q37989006-F5455BB4-5B6E-49CB-9900-341F677F02C6

P2860

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.

http://www.wikidata.org/entity/Q35172210

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase I pharmacokinetic and ph ...... relapsed/refractory leukemia.

@ast

Phase I pharmacokinetic and ph ...... relapsed/refractory leukemia.

@en

type

label

Phase I pharmacokinetic and ph ...... relapsed/refractory leukemia.

@ast

Phase I pharmacokinetic and ph ...... relapsed/refractory leukemia.

@en

prefLabel

Phase I pharmacokinetic and ph ...... relapsed/refractory leukemia.

@ast

Phase I pharmacokinetic and ph ...... relapsed/refractory leukemia.

@en

P1433

Q35172210-30B2816C-E246-4C73-B5FF-0750A27C561B

P1476

Q35172210-F9559C97-BA1C-45E3-8E8B-02F0BCA6B42A

P2093

Q35172210-04E02EDB-AA05-40C7-B3C1-518AD1F63F3F

Q35172210-1557B374-DDD4-4C15-8B15-C1ABF482FF7E

Q35172210-2396A70A-9898-41F6-8301-44DB5FB8C958

Q35172210-2BE317C4-580D-4962-9223-B2A0DFD6652C

Q35172210-3A397062-D591-41B0-93CC-2728A4331046

Q35172210-3AEEEEFF-8D55-460A-AE56-1A680DA70EF1

Q35172210-551A25AA-FF71-4107-8145-C73B169418D2

Q35172210-6BF23D87-9FBD-4DAF-9DB6-1D76565A94C7

Q35172210-7A0C30DD-81B1-450F-A4FD-04671550F2E3

Q35172210-7FB6A6F3-F8C4-4963-9FF3-BC2E526D3B99

P2860

Q35172210-09301F23-A278-40EF-BBB8-2C1224A4BFE8

Q35172210-1D59862C-00D8-4A8A-96AE-3E25654526C1

Q35172210-3391B4F9-0AF4-400A-B702-9F8577F92C1B

Q35172210-3392D749-EA21-46D7-89D5-6447DE8CE725

Q35172210-3ED99895-FCE4-4DCB-93ED-12AF2137119A

Q35172210-4E80EFA6-700D-4407-8DA7-3D5F21996BAE

Q35172210-5D3B17C0-146A-4DA5-9634-180A9BEB1897

Q35172210-6485AD81-2E39-4143-B041-50ED28DFFCF8

Q35172210-68F19A43-E6BE-4B49-B7A7-80D328F66150

Q35172210-6916B7ED-B6BC-4F03-9E85-393EAEF7F71E

P304

Q35172210-C8CD43A3-65A0-439E-B25F-A63D65B60DBD

P31

Q35172210-9EE13D8A-58DD-4078-9F75-DCA1065C0906

P356

Q35172210-422EDC4E-BD21-4F7F-B3C1-90A4AF68E688

P407

Q35172210-96039C0B-7AE9-44E9-B73D-3B1E8547488D

P433

Q35172210-9A146433-8C7E-44FB-8D20-50B40D2F6E0A

P478

Q35172210-70EDE448-3918-428D-87B5-79F001049D5C

P50

Q35172210-5339B6A0-8791-45C3-8B21-9C0A0B72C919

P577

Q35172210-7476A3A9-7601-49F3-8257-134266ECE043

P698

Q35172210-FF7B86E5-DC1E-41E1-90CF-3E0F58117E0B

P932

Q35172210-69276FA9-46D2-4CF4-8EF5-627BF1463B4D

P356

JCO.2011.34.7427

P1433

Journal of Clinical Oncology

P1476

Phase I pharmacokinetic and ph ...... relapsed/refractory leukemia.

@en

P2093

Brian D Furmanski

http://www.w3.org/2001/XMLSchema#string

Dario Campana

http://www.w3.org/2001/XMLSchema#string

Elaine Coustan-Smith

http://www.w3.org/2001/XMLSchema#string

Gerard P Mascara

http://www.w3.org/2001/XMLSchema#string

Hiroto Inaba

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Rubnitz

http://www.w3.org/2001/XMLSchema#string

Kenneth M Heym

http://www.w3.org/2001/XMLSchema#string

Lie Li

http://www.w3.org/2001/XMLSchema#string

Mihaela Onciu

http://www.w3.org/2001/XMLSchema#string

Raul C Ribeiro

http://www.w3.org/2001/XMLSchema#string

P2860

Structural and functional alterations of FLT3 in acute myeloid leukemia

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3

A small molecule-kinase interaction map for clinical kinase inhibitors

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

P304

3293-3300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.34.7427

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21768474

http://www.w3.org/2001/XMLSchema#string

P932

3158600

http://www.w3.org/2001/XMLSchema#string